share_log

Outlook Therapeutics 获得欧盟委员会用于治疗湿性 AMD 的 Lytenava(贝伐珠单抗 Gamma)的上市许可

Zhitong Finance ·  May 28 08:16

Outlook Therapeutics 获得欧盟委员会用于治疗湿性 AMD 的 Lytenava(贝伐珠单抗 Gamma)的上市许可

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment